Treatment of Punctate Inner Choroidopathy with Choroidal Neovascularization Using Corticosteroid and Intravitreal Ranibizumab

Table 1

Patient characteristics and responses to treatment.

	Intravitreal ranibizumab monotherapy	Combined corticosteroid and ranibizumab	P value
	(n = 14 eyes)	(n = 10 eyes)
Mean age	42.9	30.0	0.006
Mean follow-up	23.3 months	24.5 months	0.844
Initial BCVA	0.68 logMAR	0.82 logMAR	0.378
Final BCVA	0.34 logMAR	0.22 logMAR
Change of BCVA	-0.34 logMAR	-0.61 logMAR	0.174
Mean intravitreal injections given	3.0	1.9	0.102
Recurrent CNV (eyes)	8 (57.1%)	0 (0%)
Improved or stable BCVA (eyes)	13 (92.9%)	10 (100%)
Reduced lesions (eyes)	0 (0%)	2 (20%)
Stable lesions (eyes)	8 (57.2%)	6 (60%)
New lesions (eyes)	6 (42.8%)	2 (20%)

Improved or stable BCVA means that BCVA of the patient kept stable (less than 0.1 in change) or was improved to more than 0.1 after the treatment.